What is the appropriate dose of polyethylene glycol 3350 for a healthy 3‑year‑old child with constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Appropriate PEG 3350 Dose for a 3-Year-Old Child

For a healthy 3-year-old child with constipation, start polyethylene glycol 3350 at 0.8 g/kg/day (approximately 10–12 grams daily for an average-weight child), mixed in at least 4–8 ounces of liquid, and continue for 1–2 weeks before assessing response. 1, 2

Weight-Based Dosing Algorithm

  • Initial dose: 0.8–0.88 g/kg/day is the evidence-based starting point for children aged 2–3 years 1, 2
  • Effective maintenance dose: Most children respond to 0.7–0.8 g/kg/day after initial treatment 1, 2
  • Dose range: Can be adjusted from 0.27 g/kg/day up to 1.42 g/kg/day based on response and tolerability 2
  • For a typical 3-year-old weighing 14–15 kg, this translates to approximately 10–12 grams daily as a starting dose 2

Critical Administration Details

  • Mix the powder in at least 4–8 ounces of liquid (water, juice, soda, coffee, or tea) 1, 3
  • Juices containing sorbitol provide synergistic osmotic benefit and may enhance efficacy 1
  • Insufficient liquid volume is the most common cause of treatment failure—ensure the child drinks the full mixture and maintains adequate fluid intake throughout the day 1
  • First bowel movement typically occurs within 2–4 days of starting therapy 3

Dose Titration Strategy

  • Adjust the dose every 3 days based on stool frequency and consistency to achieve approximately 2 soft stools per day 2
  • If no response after 3–4 days of optimal dosing with confirmed adequate hydration, increase the dose incrementally (e.g., by 0.2 g/kg/day) 1, 2
  • If still no bowel movement after 3–4 days, add a bisacodyl suppository (5 mg for children) or glycerin suppository while continuing PEG 1

Treatment Duration and Maintenance

  • Continue therapy for 1–2 weeks initially to achieve optimal effect 1, 3
  • Average treatment duration in pediatric studies is 6–12 months, with efficacy maintained throughout 1
  • Do not stop abruptly once bowel movements normalize—continue maintenance dosing to prevent relapse 1

Safety Profile in Young Children

  • PEG 3350 is safe and effective in children as young as 6 months, with a 97.6% success rate in infants and toddlers 4
  • Common side effects include mild abdominal distension, flatulence, and transient diarrhea that resolves with dose adjustment 1, 4
  • No clinically significant electrolyte disturbances occur with chronic use 5

Critical Pitfalls to Avoid

  • Rule out fecal impaction before starting—may require manual disimpaction or enema first 1
  • Exclude bowel obstruction or paralytic ileus as contraindications 1
  • Ensure adequate daily fluid intake beyond the mixing liquid—PEG requires water to exert its osmotic effect 1
  • Do not assume treatment failure without first optimizing dose and confirming compliance with adequate fluid intake 1

When to Escalate Therapy

  • If constipation persists despite optimal PEG dosing for 3–4 days, add an oral stimulant laxative (senna 2.5–5 mg daily or bisacodyl 5 mg daily) to exploit complementary mechanisms 1, 5
  • Stimulant laxatives work best when given approximately 30 minutes after meals to leverage the gastrocolic reflex 1

FDA Labeling Caveat

Note that the FDA label states "should not be used by children" 3, but this reflects the original over-the-counter approval for adults only. Multiple high-quality pediatric guidelines and research studies strongly support PEG 3350 as first-line therapy for childhood constipation, with extensive safety and efficacy data in children as young as 6 months 1, 4, 2, 6. The American Gastroenterological Association and American Academy of Pediatrics explicitly endorse weight-based dosing for pediatric use 1.

References

Guideline

Pediatric Dosing of MiraLAX (Polyethylene Glycol 3350)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Polyethylene glycol for constipation in children younger than eighteen months old.

Journal of pediatric gastroenterology and nutrition, 2004

Guideline

Polyethylene Glycol 3350 (MiraLAX) for Chronic Constipation – Evidence‑Based Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation.

Canadian family physician Medecin de famille canadien, 2009

Related Questions

What is the recommended dose of Glycolax (polyethylene glycol 3350) for a 3-year-old child with moderate constipation?
What is the pediatric dosage for polyethylene glycol (PEG) for constipation relief?
What is the best laxative for a 3-year-old child with constipation?
What is the best course of action for a 2.5-year-old patient with a history of constipation, vomiting, and recent development of an awkward, stiff gait, wide stance, poor coordination, and balance, with pronated ankles, after successful treatment of constipation with MiraLAX (polyethylene glycol 3350)?
What is the treatment plan for a 10-month-old child with constipation using Restorolax (polyethylene glycol)?
What is the safest first‑line oral antidiabetic medication for an elderly patient with type 2 diabetes, given adequate renal function and common comorbidities?
What are the next management steps for a 60‑year‑old postmenopausal woman with a 2 cm, grade II, estrogen‑receptor‑positive, progesterone‑receptor‑negative, HER2‑negative multicentric invasive ductal carcinoma and a clinically palpable 2 cm axillary lymph node (cN1) after diagnostic core‑needle biopsies have been performed?
Is fondaparinux comparable to apixaban?
What factors exacerbate interstitial cystitis symptoms?
What is the maximum recommended dose of Belsomra (suvorexant)?
How is bacterial sinusitis diagnosed in an otherwise healthy adult presenting with acute rhinosinusitis symptoms (nasal congestion, purulent nasal discharge, facial pain/pressure, and reduced sense of smell)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.